Equities

Evolus Inc

Evolus Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)13.68
  • Today's Change-0.61 / -4.27%
  • Shares traded1.28m
  • 1 Year change+56.52%
  • Beta1.2807
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6354146
Total Receivables, Net312215
Total Inventory11191.76
Prepaid expenses5.703.905.08
Other current assets, total2.361.6811
Total current assets112101179
Property, plant & equipment, net7.854.564.09
Goodwill, net212121
Intangibles, net474951
Long term investments------
Note receivable - long term------
Other long term assets0.412.812.76
Total assets189178257
LIABILITIES
Accounts payable4.278.946.09
Accrued expenses242238
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total201513
Total current liabilities484758
Total long term debt1207271
Total debt1207271
Deferred income tax0.030.020.04
Minority interest------
Other liabilities, total414147
Total liabilities210159176
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital539516505
Retained earnings (accumulated deficit)(559)(497)(423)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.43)(0.34)--
Total equity(21)1882
Total liabilities & shareholders' equity189178257
Total common shares outstanding585656
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.